Rhoclone 150 mcg Injection
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Rhoclone 150 mcg Injection contains anti-D (Rho) immunoglobulin. Its labelling describes it for preventing the formation of antibodies (Rh isoimmunisation) when an Rh-negative person is exposed to Rh-positive red blood cells — for example an Rh-negative woman carrying an Rh-positive baby, or an Rh-negative person who has received an Rh-positive transfusion. It is given only by a doctor or nurse.
Product Information
The following description reflects information associated with anti-D (Rho) immunoglobulin and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the prevention of Rh isoimmunisation in Rh-negative women during and after pregnancy with an Rh-positive baby
- Described as routinely given at about 28 weeks of pregnancy and within 72 hours of birth if the baby is Rh-D positive
- Described for Rh-negative individuals who have received an incompatible transfusion of Rh-positive red blood cells
Described Dosage & Administration
- Administered only by a doctor or nurse as an injection — not self-administered
- Described as given routinely at about 28 weeks of pregnancy for Rh-D negative women
- Described as given within 72 hours of birth if the baby is confirmed Rh-D positive
Described Side Effects
The labelling describes no common side effects; where a reaction does occur it should be reported:
- No common side effects are described; any reaction should be discussed with the doctor promptly
Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- The doctor should be told about any problems with blood clotting
- The doctor should be told about any recent or planned vaccination, as immunoglobulin can affect the response to some vaccines
- The dosing schedule set by the doctor (antenatal and post-delivery) should be followed
- Any reaction should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains anti-D (Rho) immunoglobulin and is used to prevent Rh isoimmunisation in Rh-negative individuals, including during and after pregnancy with an Rh-positive baby and after an incompatible transfusion. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor or nurse as an injection, routinely at about 28 weeks of pregnancy and within 72 hours of birth if the baby is Rh-D positive. It is not self-administered.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.